12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ibrutinib regulatory update

Johnson & Johnson's Janssen-Cilag International N.V. unit submitted an MAA to EMA for ibrutinib to treat relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL). The product is under Priority Review...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >